Article

Intravitreal adjunct may improve outcomes of PDT

New York-Intravitreal triamcinolone acetonide appears to be a useful adjunct to photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) in the treatment of eyes with choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), said Richard F. Spaide, MD, at the Macula 2003 meeting here.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Related Content
Understanding cerebral/cortical visual impairment: New insights and advances in diagnosis
November 22nd 2024

Understanding cerebral/cortical visual impairment: New insights and advances in diagnosis

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Integrating imaging modalities for early detection of key microscopic abnormalities in diabetic retinopathy
November 22nd 2024

Integrating imaging modalities for early detection of key microscopic abnormalities in diabetic retinopathy

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Adverum Biotechnologies announces topline 52-week results from LUNA Phase 2 trial and 4-year OPTIC results
November 21st 2024

Adverum Biotechnologies announces topline 52-week results from LUNA Phase 2 trial and 4-year OPTIC results

USC researchers receive $6 million CIRM grant to advance novel dry AMD therapy
November 21st 2024

USC researchers receive $6 million CIRM grant to advance novel dry AMD therapy

© 2024 MJH Life Sciences

All rights reserved.